Credit: Dalin Ou via Getty Images. US biotech Merida Biosciences has launched with $121m in Series A financing to develop therapeutics targeting disease-causing antibodies in autoimmune diseases and ...

Get Instant Summarized Text (Gist) An AI-driven platform has been used to optimize an antibody, 3152-1142, to neutralize a wide range of SARS-CoV-2 variants, enhancing its potency against ...

Apri 7, 2025 — Researchers from Lawrence Livermore National Laboratory (LLNL), in collaboration with other institutions, have successfully used an AI-driven platform to preemptively optimize an ...

RhoGAM almost completely prevents this. If an Rh-negative person is pregnant with an Rh-positive fetus, there is a risk that the parent could develop antibodies against Rh-positive red blood cells if ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Spanish scientists documented a second so-called class switch in people with "repeated" mRNA COVID jabs, meaning their bodies start churning out two kinds of antibodies that learn to live with ...

In the rapidly evolving field of antibody drug discovery, the ability to efficiently characterize and screen antibodies and antibody drug conjugates (ADCs) is crucial for developing effective ...

The granted claims cover the novel design and therapeutic applications of bispecific antibodies that simultaneously inhibit CHI3L1 and PD1, key targets implicated in immune evasion by tumor cells.

BioAtla is laying off 30% of staff as the biotech searches for partners for some of its conditionally active biologic (CAB) antibodies while eking out its cash to cover a slew of clinical readouts ...

Biologics are a wide-ranging class of drugs, and there are many different types. Most biologics for Crohn's disease are monoclonal antibody treatments that help tune down the immune system’s ...